Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
Karyopharm hopes to move Xpovio earlier in the multiple myeloma treatment sequence, and data are due for Akcea/Ionis’s triglyceride regulator, for which Pfizer paid a…
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
After making investors wait more than a year, TG Therapeutics is gearing up to release results of its lead leukaemia combo, while Insmed hopes to succeed in a very tricky…
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Belantamab’s registrational Dreamm-2 study comes up short of an earlier trial and, more importantly, now seriously lags competitors’ data.
Axsome is heading to regulators in the wake of a second successful depression study, and investors are predicting huge success. What could possibly go wrong?